GHSI: AI 评分 46/100 — AI 分析 (4月 2026)

Guardion Health Sciences, Inc. operates as a specialty health sciences company, focusing on medical foods, nutraceuticals, and medical devices for vision-related conditions. Their product line includes medical foods like Lumega-Z and GlaucoCetin, and devices for vision testing.

Key Facts: AI Score: 46/100 Sector: Healthcare

公司概况

概要：

Guardion Health Sciences, Inc. develops and markets medical foods, nutraceuticals, and medical devices targeting vision health. The company's focus on macular pigment and optic nerve support differentiates it within the specialty healthcare sector, addressing specific needs in ophthalmology with products like Lumega-Z and GlaucoCetin.

GHSI是做什么的？

Guardion Health Sciences, Inc., founded in 2009 and headquartered in San Diego, California, is a specialty health sciences company dedicated to developing and commercializing innovative products for vision health. The company operates through two segments: Medical Foods and Nutraceuticals, and Medical Devices. Its flagship product, Lumega-Z, is a medical food designed to replenish and restore macular protective pigment, crucial for maintaining healthy vision. GlaucoCetin is another key product, a vision-specific medical food formulated to support and protect the mitochondrial function of optic nerve cells and improve blood flow in the ophthalmic artery for patients with glaucoma. In addition to medical foods, Guardion Health Sciences offers a range of medical devices. These include MapcatSF, which measures macular pigment optical density, and the CSV-1000 and CSV-2000 devices, standardized contrast sensitivity testing tools used by eye doctors in clinical trials, real-world vision evaluation, and industrial vision testing. These devices are marketed under the VectorVision name. The company also develops ImmuneSF, a nutraceutical formulation, and markets a portfolio of nutraceutical products under the NutriGuard brand. Guardion distributes its products through e-commerce via its online store, guardionhealth.com, expanding its reach to a broader customer base. Guardion Health Sciences aims to address unmet needs in the vision health market through science-backed products and technologies.

GHSI的投资论点是什么？

Guardion Health Sciences operates in the niche market of vision-related medical foods, nutraceuticals, and devices. The company's focus on macular degeneration and glaucoma provides a targeted approach to address prevalent eye conditions. With a gross margin of 44.0%, GHSI demonstrates the potential for profitability as it scales its operations. Key growth catalysts include expanding the market reach of Lumega-Z and GlaucoCetin, as well as increasing adoption of its VectorVision line of medical devices. The company's online distribution channel through guardionhealth.com offers a direct-to-consumer approach, potentially improving margins and customer engagement. However, the company's small market capitalization and OTC listing present liquidity and regulatory risks. The P/E ratio of 26.14 suggests investors anticipate future earnings growth, but this also implies a higher valuation that needs to be justified by strong execution.

GHSI在哪个行业运营？

Guardion Health Sciences operates within the specialty drug and medical device industry, focusing on vision care. The market for age-related macular degeneration (AMD) and glaucoma treatments is substantial and growing, driven by an aging population and increased awareness of eye health. The competitive landscape includes both pharmaceutical giants and smaller, specialized companies. Guardion differentiates itself through its focus on medical foods and nutraceuticals, offering alternative or complementary approaches to traditional pharmaceutical interventions. The company's success depends on its ability to demonstrate the efficacy and safety of its products through clinical studies and real-world evidence.

Drug Manufacturers - Specialty & Generic

Healthcare

GHSI有哪些增长机遇？

Expansion of Lumega-Z Market Reach: Lumega-Z, a medical food designed to replenish and restore the macular protective pigment, has a significant growth opportunity within the aging population. The global market for AMD treatment is projected to reach billions of dollars. By increasing awareness and distribution of Lumega-Z through targeted marketing campaigns and partnerships with eye care professionals, Guardion can capture a larger share of this growing market. Timeline: Ongoing.
Increased Adoption of VectorVision Devices: The VectorVision line of medical devices, including MapcatSF, CSV-1000, and CSV-2000, offers standardized vision testing solutions for eye doctors. By expanding the sales and marketing efforts for these devices, Guardion can increase their adoption in clinical trials, real-world vision evaluation, and industrial vision testing. The market for vision testing equipment is expected to grow. Timeline: Ongoing.
Development and Commercialization of ImmuneSF: ImmuneSF, a nutraceutical formulation, represents a growth opportunity for Guardion in the broader health and wellness market. By leveraging its expertise in formulation and distribution, Guardion can commercialize ImmuneSF through its existing e-commerce platform and expand its product portfolio. The nutraceuticals market is expected to continue its growth trajectory. Timeline: Ongoing.
Geographic Expansion: Guardion Health Sciences currently focuses on the United States market. Expanding its operations to international markets, such as Europe and Asia, represents a significant growth opportunity. By adapting its products and marketing strategies to local regulations and consumer preferences, Guardion can tap into new revenue streams and diversify its geographic footprint. Timeline: 2-3 years.
Strategic Partnerships and Acquisitions: Guardion can pursue strategic partnerships and acquisitions to expand its product portfolio, market reach, and technological capabilities. Collaborating with other companies in the vision care industry or acquiring complementary businesses can accelerate Guardion's growth and strengthen its competitive position. Timeline: Ongoing.

Guardion Health Sciences operates in two segments: Medical Foods and Nutraceuticals, and Medical Devices, diversifying its revenue streams within the vision health market.
The company offers Lumega-Z, a medical food designed to replenish and restore macular protective pigment, addressing a critical need in age-related macular degeneration.
GlaucoCetin, a vision-specific medical food, supports and protects the mitochondrial function of optic nerve cells, targeting glaucoma patients.
Guardion's VectorVision line includes devices like MapcatSF, CSV-1000, and CSV-2000, providing standardized vision testing solutions for eye doctors.
The company distributes its products through e-commerce via guardionhealth.com, enabling direct-to-consumer sales and broader market access.

GHSI提供哪些产品和服务？

Develops and markets Lumega-Z, a medical food for macular pigment replenishment.
Offers GlaucoCetin, a vision-specific medical food for optic nerve support in glaucoma patients.
Provides MapcatSF, a medical device measuring macular pigment optical density.
Manufactures and sells CSV-1000 and CSV-2000 devices for standardized contrast sensitivity testing.
Develops ImmuneSF, a nutraceutical formulation.
Markets a portfolio of nutraceutical products under the NutriGuard brand.
Distributes products through e-commerce via guardionhealth.com.

GHSI如何赚钱？

Develops and sells medical foods targeting specific vision conditions.
Manufactures and sells medical devices for vision testing and evaluation.
Markets and distributes nutraceutical products for overall health and wellness.
Generates revenue through direct-to-consumer sales via its online store, guardionhealth.com.

Patients with age-related macular degeneration (AMD).
Patients with glaucoma.
Eye doctors and optometrists using vision testing devices.
Individuals seeking nutraceutical products for overall health and wellness.

Specialized product portfolio focused on vision health.
Proprietary formulations for medical foods like Lumega-Z and GlaucoCetin.
Established brand recognition in the vision care market.
Direct-to-consumer distribution channel through guardionhealth.com.

什么因素可能推动GHSI股价上涨？

Ongoing: Expansion of Lumega-Z market reach through targeted marketing campaigns and partnerships with eye care professionals.
Ongoing: Increased adoption of VectorVision devices in clinical trials, real-world vision evaluation, and industrial vision testing.
Ongoing: Development and commercialization of ImmuneSF through existing e-commerce platform.
Upcoming: Potential strategic partnerships and acquisitions to expand product portfolio and market reach.
Upcoming: Positive clinical trial results demonstrating the efficacy of Lumega-Z or GlaucoCetin.

GHSI的主要风险是什么？

Potential: Competition from larger pharmaceutical and medical device companies with greater resources.
Potential: Regulatory changes affecting the medical food and nutraceutical industries.
Potential: Product liability claims related to the safety or efficacy of Guardion's products.
Ongoing: Economic downturn affecting consumer spending on healthcare products.
Ongoing: Risks associated with operating as an OTC-listed company, including limited liquidity and regulatory oversight.

GHSI的核心优势是什么？

Specialized product portfolio targeting vision health.
Proprietary formulations for medical foods.
Direct-to-consumer distribution channel.
Established brand recognition in the vision care market.

GHSI的劣势是什么？

Small market capitalization.
Limited financial resources.
Dependence on a small number of key products.
OTC listing presents liquidity and regulatory risks.

GHSI有哪些机遇？

Expansion of Lumega-Z market reach.
Increased adoption of VectorVision devices.
Development and commercialization of new products.
Geographic expansion into international markets.

GHSI面临哪些威胁？

Competition from larger pharmaceutical and medical device companies.
Regulatory changes affecting the medical food and nutraceutical industries.
Product liability claims.
Economic downturn affecting consumer spending on healthcare products.

GHSI的竞争对手是谁？

Accura Science Ltd. — Focuses on developing and commercializing innovative diagnostic and therapeutic products. — (ACRDF)
Acura Science Ltd. — Offers a range of products and services in the healthcare sector. — (ACRHF)
Bausch Health Companies Inc. — A large pharmaceutical company with a diverse portfolio of products, including vision care products. — (BRRGF)
China National Accord Medicines Corporation Ltd. — A Chinese pharmaceutical company involved in the production and distribution of medicines. — (CHNC)
Hydrate IV Bar — Focuses on providing IV hydration therapy services. — (HDRPF)

Key Metrics

MoonshotScore: 46/100

Company Profile

CEO: Mark Goldstone
Headquarters: San Diego, US
Employees: 9
Founded: 2019

AI Insight

AI analysis pending for GHSI

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Guardion Health Sciences, Inc. do?

Guardion Health Sciences, Inc. is a specialty health sciences company focused on developing and commercializing innovative products for vision health. The company operates in two segments: Medical Foods and Nutraceuticals, and Medical Devices. Its key products include Lumega-Z, a medical food designed to replenish and restore macular protective pigment, and GlaucoCetin, a vision-specific medical food formulated to support and protect the mitochondrial function of optic nerve cells. Additionally, Guardion offers a range of medical devices under the VectorVision brand for standardized vision testing.

What do analysts say about GHSI stock?

As of March 17, 2026, there is no readily available analyst consensus on Guardion Health Sciences (GHSI) due to its OTC listing and small market capitalization. Investors should conduct their own due diligence and consider the company's financial performance, growth prospects, and risk factors before making any investment decisions. Key valuation metrics include the P/E ratio of 26.14 and the gross margin of 44.0%. Growth considerations include the potential for expanding the market reach of Lumega-Z and GlaucoCetin, as well as increasing adoption of its VectorVision line of medical devices.

What are the main risks for GHSI?

The main risks for Guardion Health Sciences include competition from larger pharmaceutical and medical device companies, regulatory changes affecting the medical food and nutraceutical industries, and potential product liability claims. Additionally, as an OTC-listed company, GHSI faces risks associated with limited liquidity, financial disclosure, and regulatory oversight. An economic downturn could also affect consumer spending on healthcare products, impacting the company's revenue and profitability. Investors should carefully consider these risks before investing in GHSI.